Cloud-clone
SKU(재고 관리 코드):LMB801Hu
Magnetic Luminex Assay Kit for Prekallikrein (PK) ,etc.
Magnetic Luminex Assay Kit for Prekallikrein (PK) ,etc.
Product No.
LMB801Hu
Organism Species
Homo sapiens (Human).
Sample Type
plasma
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.1-100ng/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.033 ng/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Prekallikrein (PK) ,etc..
No significant cross-reactivity or interference between Prekallikrein (PK) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Prekallikrein (PK) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Prekallikrein (PK) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 96-103 | 99 |
| EDTA plasma(n=5) | 90-97 | 93 |
| heparin plasma(n=5) | 92-99 | 96 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Prekallikrein (PK) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Prekallikrein (PK) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Prekallikrein (PK) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-93% | 93-101% | 86-95% | 84-91% |
| EDTA plasma(n=5) | 78-96% | 90-98% | 95-103% | 80-101% |
| heparin plasma(n=5) | 80-99% | 84-98% | 85-104% | 78-90% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:PK) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Int J Immunopathol Pharmacol | Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes PubMed: 25964383 |
| Thromb Res | Factor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation PubMed: 26706311 |
| Thrombosis Research | Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation Pubmed:26706311 |
| Annals of Laboratory Medicine | The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T) Pubmed: 30430790 |
| J Cell Mol Med | Huaier shows anti©\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF©\1¦Á pathway 33377619 |
| J Thromb Thrombolysis | Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors Pubmed:34993714 |
| Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
| RPB801Hu01 | Recombinant Prekallikrein (PK) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB801Hu01 | Polyclonal Antibody to Prekallikrein (PK) | WB; IHC; ICC; IP. |
| MAB801Hu22 | Monoclonal Antibody to Prekallikrein (PK) | WB; IHC; ICC; IP. |
| SEB801Hu | ELISA Kit for Prekallikrein (PK) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB801Hu | Magnetic Luminex Assay Kit for Prekallikrein (PK) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
Share
